Overview
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)
Status:
Completed
Completed
Trial end date:
2008-06-01
2008-06-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
The objective of this follow-up study is to evaluate whether corifollitropin alfa (Org 36286) treatment for the induction of multifollicular growth in women undergoing controlled ovarian stimulation (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) is safe for pregnant participants and their offspring.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
Follicle Stimulating Hormone
Ganirelix
Hormones
Progesterone
Criteria
Inclusion Criteria:- Participants who participated in base study P05690 (NCT00702845) and received at least
one dose of either corifollitropin alfa (Org 36286) or recFSH in base study P05690;
- Ongoing pregnancy confirmed by ultrasound at least 10 weeks after embryo transfer in
base study P05690;
- Able and willing to give written informed consent.
Exclusion Criteria:
- None